Kurma Partners closed its fourth and largest venture fund, raising €215 million, targeting investments in disruptive therapeutic companies. Kurma said previous exits included Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. The fund focuses on early discovery and development bets designed to support portfolio companies through to clinical proof, with a global investment footprint consistent with Kurma’s history of life-science dealmaking. Industry impact: a fund of this size signals continued institutional appetite for venture-backed therapeutics, particularly at moments when investors increasingly demand clearer differentiation and de-risked clinical pathways.